Active, not recruitingPhase 1NCT04704661
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Studying NON RARE IN EUROPE: Adenocarcinoma of stomach
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Kanwal P RaghavUniversity of Texas MD Anderson Cancer Center LAO
- Intervention
- Biopsy Procedure(procedure)
- Enrollment
- 51 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (23)
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
- Los Angeles General Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- UF Health Cancer Institute - Gainesville, Gainesville, Florida, United States
- Memorial Hospital East, Shiloh, Illinois, United States
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri, United States
- Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Siteman Cancer Center-South County, St Louis, Missouri, United States
- Siteman Cancer Center at Christian Hospital, St Louis, Missouri, United States
- NYP/Weill Cornell Medical Center, New York, New York, United States
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04704661 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Adenocarcinoma of stomach
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07431281Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2AstraZeneca
- ACTIVE NOT RECRUITINGNCT07448493Local Treatment Strategies for Brain Metastases of Gastric and Esophageal CancerBlokhin's Russian Cancer Research Center
- RECRUITINGPHASE1, PHASE2NCT07262619EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsEikon Therapeutics
- RECRUITINGPHASE2NCT07070466Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEAMassachusetts General Hospital
- RECRUITINGPHASE2NCT07102901Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaJiangsu HengRui Medicine Co., Ltd.
- RECRUITINGPHASE2NCT07212933The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled TrialChinese PLA General Hospital
- RECRUITINGNCT07032961A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies ScreeningNanfang Hospital, Southern Medical University
- RECRUITINGPHASE1, PHASE2NCT06710756Lead-212 PSV359 Therapy for Patients With Solid TumorsPerspective Therapeutics
See all trials for NON RARE IN EUROPE: Adenocarcinoma of stomach →